Insulin icodec/semaglutide
Jump to navigation
Jump to search
| Combination of | |
|---|---|
| Insulin icodec | Insulin analog |
| Semaglutide | GLP-1 receptor agonist |
| Clinical data | |
| Trade names | IcoSema |
| Legal status | |
| Legal status |
|
Insulin icodec/semaglutide, or IcoSema, is a combination medication of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk. It is injected once weekly.[1][2][3]
References
- ^ Kalra, Sanjay; Bhattacharya, Saptarshi; Kapoor, Nitin (August 2021). "Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)". Diabetes Therapy. 12 (8): 2133–2147. doi:10.1007/s13300-021-01113-y. ISSN 1869-6953. PMC 8342688. PMID 34268675.
- ^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 5 November 2023.
- ^ "Novo Nordisk's Insulin Products, Pipeline May Energize The Stock (NYSE:NVO) | Seeking Alpha". seekingalpha.com. 12 February 2020. Retrieved 5 November 2023.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Combination diabetes drugs
- GLP-1 receptor agonists
- Experimental diabetes drugs
- Peptide therapeutics
- Insulin receptor agonists